Search results
Showing 466 to 480 of 1423 results for primary care
Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)
This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
How to register with us as a medical technologies stakeholder.
How to register with us as a medical technologies stakeholder.
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
social care services. By joining, you'll have the opportunity to make a difference in the lives of others by developing health and...
social care services. By joining, you'll have the opportunity to make a difference in the lives of others by developing health and...
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
This guideline covers recognising and managing antisocial behaviour and conduct disorders in children and young people aged under 19. It aims to improve care by identifying children and young people who are at risk and when interventions can prevent conduct disorders from developing. The guideline also makes recommendations on communication, to help professionals build relationships with children and young people and involve them in their own care.